Work

Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers

Year: 2020

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs19-p1-19-29

Authors: Joannes Ettl, Jennifer Litton, Hope S. Rugo, Lida Mina, Miguel Martin, Nicholas Turner, Henri Roché, Zev Wainberg, Johann de Bono, Tiziana Usari, Mohamed Elmeliegy, Silvana Lanzalone, Akos Czibere, Liza DeAnnuntis, Sara A. Hurvitz

Institutions: TUM Klinikum, Technical University of Munich, The University of Texas MD Anderson Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, Banner MD Anderson Cancer Center, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Institute of Cancer Research, Royal Marsden Hospital, Institut universitaire du cancer de Toulouse Oncopole, University of California, Los Angeles, Los Angeles Medical Center, Pfizer (Italy), Pfizer (United States), UCLA Jonsson Comprehensive Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3013762877

Cites:

Cited by:

Related to: 10